demonstrated in 36% patients (N = 36). TEs occurred in 11 patients before kidney transplant. Low PS and antithrombin were found in 9/86 (10.5%) and 2/89 (2.2%) children, respectively. Heterozygosity for FLV and PGM were found in 5/81 (6.2%) and 1/93(1.1%) children, respectively. A post-transplant thrombotic event occurred in 10 children (10%); six involved the renal transplant. The association between a history of a pretransplant thrombotic event and post-operative renal graft thrombosis approached, but did not reach significance (P = 0.071). There was no association between preoperative screening abnormalities and post-operative TEs. Graft loss due to a thrombotic event occurred in two patients; none had underlying thrombophilia.
Our data suggest that the utility of universal, comprehensive preoperative thrombophilia testing is not beneficial in determining risk of post-operative graft thrombosis.
Thrombophilia testing may be considered in a select population with a history of pretransplant thrombotic event.
both retrospective and prospective studies in renal transplant recipients. [8] [9] [10] [11] [12] The conclusions drawn by these studies are limited because of study design, inconsistency in the thrombophilic risk factors studied and variable follow-up period. While the prevalence of inherited thrombophilia such as FVLM or PGM is unknown in children awaiting renal transplant, acquired thrombophilia is particularly common in children with nephrotic syndrome as well as those with ESRD. [13] [14] [15] [16] Despite the high prevalence of acquired thrombophilia in this population, the incidence of thrombosis is far less frequent.
Some authors have suggested pretransplant thrombophilia evaluation to identify patients at high risk of post-transplant graft thrombosis. By identifying this subset of children, tailored perioperative anticoagulation to reduce graft loss due to thrombosis and favorably impact immediate graft survival has been proposed. However, the utility of universal thrombophilia screening in children with ESRD awaiting renal transplant is controversial and is not an accepted standard of care in all pediatric transplant centers. Moreover, placing all children identified to have thrombophilia on post-transplant anticoagulation can increase the risk of bleeding complications. The aim of this retrospective study was to evaluate whether identifying children with thrombophilia during the pretransplant evaluation predicted post-transplant graft thrombosis. Furthermore, it aimed to evaluate whether thrombophilia testing predicted graft survival at 3 months, 1 year, and 5 years after transplant. Our hypothesis was that thrombophilia does not predict post-transplant graft thrombosis or graft survival.
| MATERIAL S AND ME THODS

| Patient characteristics and data collection
We reviewed 100 kidney transplants performed in 100 children, We included all patients who underwent thrombophilia evaluations and were subsequently transplanted at our center. Repeat kidney transplant recipients as well as recipients of prior other solid-organ transplants were included and thrombophilia evaluations occurred prior to their kidney transplant. Our patient cohort did not represent 100 consecutive transplant recipients at our center. 
| Outcome measures
| Statistical analysis
Data were analyzed using descriptive and comparative statistics. 
| RE SULTS
| Patient characteristics
A total of 100 kidney transplant recipients were included for analysis between January 2005 and December 2013. The median age at transplant was 14 years (IQR: 10-16 years). The majority of patients were Hispanic and White (43% and 31%, respectively) and male (66%). Eighty-nine percent of patients had received a form of renal replacement therapy prior to transplantation; of those, 57% were treated with hemodialysis. Diagnoses reflecting causes of ESRD were representative of national trends ( Table 1 ). The majority of our transplant recipients (63%) received living-donor organs. All of our transplant recipients received induction with basiliximab and methylpredisone, followed by either corticosteroid avoidance or minimization, based on clinical indication. Our patient population included two prior heart transplant recipients, as well as one patient who received a second renal graft.
| Thrombophilia testing
Not all children had complete thrombophilia evaluations reflecting the evolution of testing over time, but they were performed, at least in part, in all 100 pediatric transplant recipients included in our co- 
| Post-transplant thrombosis and risk factors
Patients were followed for a median of 3. 
| Kidney transplant outcomes
Graft function and survival, antibody-mediated and cellular rejection rates, and patient survival reflected national trends at 3 months, 1 year, and 3 years after kidney transplantation (Table 3 ).
Graft loss due to a thrombotic event occurred in two patients; none of them had underlying thrombophilia. History of a pretransplant thrombotic event was associated with worse graft survival at 3-year follow-up (P < 0.005), but not at 3 months or 1 year (P > 0.05 for both). Similarly, a post-operative thrombotic event was associated with poorer graft survival at 3 months, 1 year and 3 years of follow-up (P < 0.05). There was no association found between donor type, age at transplantation, sex, dialysis modality, causes 
| D ISCUSS I ON
Kidney transplantation currently remains the best treatment modality for ESRD. Graft and patient survival continue to improve over the last decades, 1 in part owing to improved surgical techniques, better immunosuppression and optimal management of infections.
Thrombosis in pediatric graft recipients, although rare, is a significant cause of graft loss, especially in the early post-operative period.
Being able to identify patients who might benefit from perioperative anticoagulation, prior to proceeding with kidney transplantation, could potentially decrease rates of catastrophic peri-and post-operative thrombotic outcomes resulting in graft loss.
Patient with thrombophilic risk factor (n = 36)
Patients without thrombophilic risk factor (n = 64) P 
TA B L E 3 Renal function and graft outcome in patients with or without thrombophilia
In our cohort of 100 patients, six had a graft-related thrombotic event in the post-operative observational period; two of these events resulted in graft loss. FSGS as cause of ESRD and Black and Asian were found to be associated with post-transplant graft-related thrombosis. Of the six patients with post-transplant graft thrombosis, only two had thrombophilia (FVLM and AT deficiency). None of the thrombophilia markers evaluated prior to kidney transplantation in our patient population were associated with post-transplant thrombosis that resulted in graft loss. Heterozygosity for FVL was associated with increased risk of any thrombosis (ie, not specifically graft related) after transplantation (P: 0.034). Heterozygosity for FVL has previously been assessed as a risk factor for graft thrombosis and worse outcomes after transplantation 11, 18 ; however, as also reflected by our study findings, data remain inconclusive to date, especially in pediatric kidney transplant recipients. 19 In a recent cohort described by Rodicks et al, 20 children with thrombophilia had three times higher odds of having a vascular complication but lacked sufficient power to show statistical significance. In the cohort described, only 28/83 patients had some form of a thrombophilia screeningdetails regarding screening were not provided, and the patients undergoing screening may well have been higher risk at baseline, based on prior clinical events.
Our retrospective study demonstrates rates of inherited and acquired thrombophilia in a pediatric population that is similar to published adult data. 8 Pediatric literature is very limited in suggesting management 21, 22 with the largest cohort published to date encompassing 70 children. Our rate of graft loss from thrombosis (2%) is similar to recently reported data from NAPRTCS 2014 (6.6%), and the rate of thrombotic events (10%) after transplantation in our pediatric population is reflective of similar trends published among adult kidney transplant recipients.
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Nephrotic syndrome is a known risk factor for thrombosis, especially in smaller graft recipients. 23 Similarly, we found that FSGS We found an association between Black and Asian race with post-operative renal graft thrombosis which has not been re- East Asia, but rare in the Black population. 24 Racial differences in renal graft thrombosis or graft loss is not reported but it is likely that non-thrombophilia-related factors account for the association between race and graft thrombosis. 25 Moreover, in our cohort, of the 21 patients with FSGS, four were African American.
Of the four African Americans, one experienced graft thrombosis This group treated those with positive thrombophilia with UFH for 2 weeks followed by LMWH for another 8 weeks followed by aspirin. However, they reported one serious bleeding complication needing a surgical intervention. Thus, the risks of thrombosis and bleeding have to be carefully balanced especially in the immediate post-operative period.
Our analysis of 100 pediatric patients who underwent thrombophilia testing prior to kidney transplantation is the largest pediatric study, to our knowledge, attempting to assess the utility of thrombophilia testing as part of pre-kidney transplant evaluation. However, it does have some limitations that warrant discussion. The retrospective nature makes it difficult to reach definitive conclusions about association of factors with post-transplant thrombotic events.
Furthermore, the data were collected from a single, large North
American center, and thus, our findings are not easily generalizable to all centers. Additionally, thrombophilia testing was not comprehensive and standardized, and this may limit the ability to draw any definitive conclusions about impact of inherited or acquired thrombophilias on post-transplant outcomes. Finally, 8 of our patients received perioperative anticoagulation beyond standard intra-operative heparin, in response to positive thrombophilia in combination with pretransplant thrombotic, medical, or surgical concerns. We recognize that the addition of perioperative anticoagulation in this subset adds limitations when drawing conclusions from our findings.
| CONCLUSION
In summary, our data suggest that the utility of preoperative thrombophilia testing is not beneficial in determining the risk of post-operative graft thrombosis. Thrombophilia testing may be considered in a select population with a history of pretransplant thrombotic event. Future prospective studies with systematic thrombophilia testing in a large, multicenter cohort would be useful in confirming these findings. Additionally, there are no consensus guidelines, to date, on optimal anticoagulation prophylaxis in the perioperative and immediate post-transplant period. Anticoagulating all patients with thrombophilia may lead to increased rates of bleeding complications, a serious risk that needs to be carefully considered. The appropriate anticoagulation regimen, in the absence of consensus guidelines, is likely best determined by a multidisciplinary transplant team including pediatric transplant surgeons, nephrologists, and hematologists.
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